Introduction {#sec1}
============

In developing mammals, hematopoiesis initially occurs extraembryonically, most prominently in the yolk sac ([@bib51]), and later arises within the embryo in the aorta-gonad-mesonephros (AGM) region ([@bib17; @bib31]) and developing endocardium ([@bib36]). Definitive hematopoietic stem cells (HSCs), which are responsible for blood production throughout life, first detectibly emerge in the AGM ([@bib33]) and colonize the fetal liver (FL), ultimately occupying niches in the bone marrow (reviewed in [@bib32]). The specification of blood is closely coordinated with the specification of blood vessels, and genetic evidence supports the notion of a shared ontogeny. For example, murine embryos null for *Kdr* (also known as *Flk1*) do not develop blood islands or blood vessels and die between embryonic development days 8.5 and 9.5 ([@bib48]). In chimeric embryos, *Kdr* null cells are not detected in later sites of hematopoiesis such as the FL or adult bone marrow but are found in other mesodermal tissues like heart, kidney, and muscle ([@bib49]). In fact, endothelial cells and hematopoietic cells can be observed in vitro to arise from the same mesodermal progenitors, called hemangioblasts ([@bib6]).

Previously, our group has isolated human embryonic stem cells (ESCs) whose pluripotent state is maintained in vitro by exogenous growth factor signaling, particularly fibroblast growth factor (FGF), insulin or insulin-like growth factor, and transforming growth factor ([@bib2; @bib4; @bib57; @bib59; @bib61; @bib65]). These ESCs, in contrast to their ephemeral progenitor counterparts in vivo, can be cultured for many generations in the pluripotent state---they are fortuitously "trapped" in this state by the exogenous growth factor signaling, which sustains the expression of master transcription factors, including *POU5F1*, *SOX2*, and *NANOG*. These same factors, when ectopically expressed, can induce somatic cells to adopt a pluripotent stem (iPS) state ([@bib55; @bib54; @bib68]). Once iPS cells are reprogrammed, the ectopic factors are no longer required, as the endogenous factors can be maintained by the appropriate exogenous growth factor signaling.

A concept that thus emerges from these studies is that a core set of factors is central to both the induction and maintenance of a particular cell state. There are now numerous examples of inducing a desired cell state by the ectopic expression of key factors (reviewed in [@bib39]), for example, reprogramming fibroblasts to cells with characteristics of cardiomyocytes or hemogenic endothelium ([@bib20; @bib40]). In this study, we did not set out to reprogram cells per se; rather, we set out to determine the feasibility of employing core factors to maintain progenitors in culture. We hypothesized it might be possible to expand progenitor cells---without a priori knowledge of the exact exogenous signaling factors required for their maintenance in vitro---merely by ectopically expressing key genes. We identify six factors, *Gata2*, *Lmo2*, *Mycn*, *Pitx2*, *Sox17*, and *Tal1*, that collectively establish and maintain a proliferative state with hemangioblast potential.

Results {#sec2}
=======

Identifying Factors that Maintain Hemangioblast Potential {#sec2.1}
---------------------------------------------------------

We screened for factors that might maintain hematopoietic progenitors in culture by examining candidate genes that either had literature support for their role in hematopoiesis (for example, [@bib3; @bib13; @bib41]) and/or were expressed in FL HSCs. The screen involved electroporating combinations of transcription factors and miRNAs encoded on doxycycline inducible cassettes into murine ESCs stably via the PiggyBac transposase system ([Figures 1](#fig1){ref-type="fig"}A and 1B). Electroporated cells were differentiated on Matrigel, following a previous established protocol ([@bib5]), to mesoderm cells, and then doxycycline was added to activate the ectopic genes as the cells were further differentiated toward hemogenic endothelium. Four days after the introduction of doxycycline, rare domed colonies formed with tight, defined edges ([Figure 1](#fig1){ref-type="fig"}C, top image). The colonies, composed of small adherent cells, occurred at a frequency of 1 to 2 of 1,000 ESCs transfected with a combination of eight transcription factors and one miRNA, and did not arise in transfected cell populations in the absence of doxycycline ([Figure 1](#fig1){ref-type="fig"}D, compare first two bars; data not shown). The domed colonies were observed in multiple independent ESC lines ([Figure 1](#fig1){ref-type="fig"}E, first bar). These colonies resembled early blast colonies before they differentiate into both endothelial and hematopoietic cells ([@bib25]), except that they continued to grow without apparent differentiation.

In the presence of doxycycline, the cells in the domed colonies were often expandable; that is, the colonies could be picked under a dissecting microscope, gently dissociated with EDTA, and replated on Matrigel and continue to proliferate. The expanding colonies (cultured 11 to 21 days) tended to lose their domed morphology, forming loose associations of scattered cells ([Figure 1](#fig1){ref-type="fig"}C, bottom image). When doxycycline was withdrawn from the expanded populations of cells in N2B27 medium supplemented with the growth factors BMP4, FGF2, VEGF, and the small molecules SB431542 and Br-cAMP (vasculogenic mixture or Vm, following the naming convention used previously; [@bib5]), the cells expressed PECAM1 and CDH5, surface markers of endothelial cells, at efficiencies ranging from 21% to 87% ([Figure 1](#fig1){ref-type="fig"}F, compare top and bottom graphs, first column). When released from doxycycline and placed in medium supplemented with stem cell factor (SCF), Wnt agonist CHIR99021, interleukin-3, and FLT3L (referred to collectively as SCIF), factors that favor early hematopoiesis ([@bib44; @bib56]), in a hypoxic (1.5% O~2~) atmosphere, cells were observed to express the canonical hematopoietic marker CD45 ([Figure 1](#fig1){ref-type="fig"}G, compare top and bottom graphs, first column). The ability of the isolates to generate CD45^+^ cells was less efficient and even more variable (1% to 23% of the population) than the ability of the same isolates to produce endothelial-like cells, suggesting that the emergence of the blood cells required a more complex configuration of ectopic factors to be present in the isolates.

To determine which of the nine factors might be responsible for these phenotypes, dropout experiments were conducted. Each of these nine factors was removed one at a time from the combination to determine which were required for domed colony formation. The removal of *Mycn* or *Sox17* reduced colony numbers by 4- or 11-fold, respectively ([Figure 1](#fig1){ref-type="fig"}D). Conversely, *Mycn* and *Sox17* together drove the formation of domed colonies in three independent ES lines with frequencies comparable to cells transfected with all nine factors ([Figure 1](#fig1){ref-type="fig"}E), although the colony sizes induced by the two factors alone tended to be smaller (data not shown). Next, to determine which factor(s) were required for the production of endothelial or blood cells, additional dropout experiments were performed ([Figures 1](#fig1){ref-type="fig"}F and 1G). In these experiments, *Mycn* and *Sox17* were always present in the factor combination to ensure colony formation. The experiments revealed that the absence of *Tal1* significantly reduced the ability of the isolates to express endothelial markers upon the withdrawal of doxycycline ([Figure 1](#fig1){ref-type="fig"}F). In addition, the absence of *Lmo2*, *Pitx2*, *Gata2*, or *Tal1* significantly reduced the ability of the isolates to produce CD45^+^ cells ([Figure 1](#fig1){ref-type="fig"}G). These data together indicated that six transcription factors, *Gata2*, *Lmo2*, *Mycn*, *Pitx2*, *Sox17*, and *Tal1*, collectively imposed a program in cells that (1) trapped them in a proliferative state and (2) endowed them with the potential to differentiate toward either blood or endothelial fates, once one or more of the factors was downregulated by the removal of doxycycline.

Expandable Hemangioblasts Give Rise to Functional Endothelial Cells, Multilineage Blood Cells, and Smooth Muscle Cells {#sec2.2}
----------------------------------------------------------------------------------------------------------------------

Single colonies, now derived with only the six transcription factors in independent ES lines, were isolated, expanded, and cryopreserved. The cells, which we dubbed "expandable hemangioblasts" (eHBs), were confirmed to express all six factors ectopically ([Figure S1](#app3){ref-type="sec"}A available online) and then were tested for their ability to differentiate to select cell types once released from the progenitor state by the withdrawal of doxycycline.

First, cells were cultured in Vm for 3 days. In contrast to control cells maintained with doxycycline, these cells dually expressed the endothelial markers PECAM1 and CDH5 ([Figure 2](#fig2){ref-type="fig"}A) and efficiently took up acetylated low-density lipoprotein (Ac-LDL) ([Figure 2](#fig2){ref-type="fig"}B). The cells were furthermore able to form capillary-like tubular networks ([Figure 2](#fig2){ref-type="fig"}C) with lumen ([Figure S1](#app3){ref-type="sec"}B) when embedded within Matrigel. Collectively, these data indicate that eHBs can differentiate into functional endothelial cells.

The eHBs were next cultured in medium supplemented with SCIF in a hypoxic (1.5% O~2~) atmosphere to induce hematopoiesis. We employed markers previously used to trace the ontogeny of hematopoietic populations in early sites of hematopoiesis, including the yolk sac and AGM region ([@bib37; @bib56]) and/or used to trace the differentiation of hemangioblasts to hematopoietic cells through an endothelial-like state (hemogenic endothelium) ([@bib25]). In a time-dependent fashion, the eHBs appeared to give rise to blood progeny by transiting through an intermediate state in which the endothelial markers TIE2 or CDH5 were coexpressed with the blood markers CD41 or CD45 ([Figures 2](#fig2){ref-type="fig"}D and [S1](#app3){ref-type="sec"}C). The transient CDH5^+^ cells were able to take up Ac-LDL ([Figure S1](#app3){ref-type="sec"}D), which supports the notion of their endothelial-like nature, although their ability to do so was not as efficient as the eHB-derived endothelial cells (compare [Figures 2](#fig2){ref-type="fig"}B and [S1](#app3){ref-type="sec"}D). To confirm that the blood cells indeed arose from these putative hemogenic endothelial intermediates, the differentiating cells were sorted into CDH5^+^ and CDH5^−^ populations 2 days into the culture and then cultured for 2 days further. The CDH5^+^ cells robustly gave rise to CD45^+^ cells, in contrast to their CDH5^−^ counterparts ([Figure S1](#app3){ref-type="sec"}E). These data indicate that eHBs give rise to blood cells through an endothelial-like intermediate state, in a manner consistent with previously described emerging hematopoietic populations either in vitro or in vivo.

The eHBs were next tested for their ability to produce hematopoietic cells of different lineages. When placed in conditions akin to those previously described to promote erythropoiesis ([@bib52]), the cells gave rise to TER119^+^ erythrocytes (many of which were also CD71^+^; [Figure 2](#fig2){ref-type="fig"}E) that abundantly expressed embryonic hemoglobin, but quite poorly expressed adult hemoglobin ([Figure S1](#app3){ref-type="sec"}F). This result indicates that the eHBs preferentially give rise to primitive hematopoiesis. When differentiated in conditions similar to those previously employed to generate macrophages ([@bib7]), the eHBs produced CD45^+^/CD11B^+^ (Mac-1) macrophages ([Figures 2](#fig2){ref-type="fig"}F and [S1](#app3){ref-type="sec"}G). When differentiated in Stemline II medium (Sigma) supplemented with SCIF and the megakaryocyte cytokine TPO, the cells gave rise to megakaryocytes and proplatelets, as indicated by the dual expression of the markers CD42D ([@bib53]) and CD41 ([Figure 2](#fig2){ref-type="fig"}G) and the presence of multinucleated cells ([Figure S1](#app3){ref-type="sec"}H). Finally, when differentiated in medium supplemented with SCIF, the eHBs also produced, albeit quite inefficiently, BFU-Es (erythrocyte progenitors), CFU-G/M/GMs (granulocyte and/or macrophage progenitors), and CFU-GEMMs (granulocyte, erythrocyte, macrophage, and megakaryocyte progenitors) ([Figure S1](#app3){ref-type="sec"}I). Together, these data indicate the eHBs, when released from control of the ectopic factors, are capable of undergoing multilineage hematopoiesis.

Next, the eHBs were assayed for their potential to give rise to smooth muscle cells, a capacity also attributed to hemangioblasts ([@bib66]). After 3 days, differentiation on collagen IV in conditions previously shown to promote the differentiation of smooth muscle cells ([@bib64]), the eHBs gave rise to progeny ([Figure S1](#app3){ref-type="sec"}J) that expressed smooth muscle actin (ACTA2) and the additional smooth muscle markers *Cnn1* (calponin 1), *Myh11* (*smMHC*), and *Tagln* (*Sm22α*) (reviewed in [@bib38]) ([Figures 2](#fig2){ref-type="fig"}H and [S1](#app3){ref-type="sec"}K). These data indicate that besides blood and endothelial potential, the eHBs also possess smooth muscle potential.

Finally, we challenged the eHBs to give rise to cells not considered to be the progeny of hemangioblasts. The cells were tested for their ability to produce cardiomyocytes, which arise from progenitors that are related to hemangioblasts, but distinguishable from them ([@bib21; @bib22]). Aggregates of eHBs and their parent ESC lines were differentiated in conditions based on previous studies ([@bib45; @bib70]) designed to promote cardiomyocyte differentiation. In contrast to the ESC lines, spontaneously beating cardiomyocytes did not arise detectibly from the eHBs ([Figures S1](#app3){ref-type="sec"}L and S1M). Instead, at least some of their surviving progeny appear to differentiate into smooth muscle cells under these conditions ([Figure S1](#app3){ref-type="sec"}M). Taken together, these data suggest that when released from the ectopic factors, the eHBs preferentially give rise to blood and vascular lineages, evidence that supports their putative hemangioblast identity.

To determine how long in culture the six ectopic factors could maintain the eHB state, two eHB lines were passaged heavily---approximately 117 population doublings, an expansion of over 10^35^ from the founding cells---and then differentiated into endothelial, blood, or smooth muscle cells ([Figure S1](#app3){ref-type="sec"}N). Even after this extensive passaging, both cell lines were still competent to produce the three cell types, but tended to do so with a reduced efficiency, an effect associated in one line with the silencing of ectopic *Gata2* ([Figure S1](#app3){ref-type="sec"}A).

The Six Factors Can Induce the eHB State {#sec2.3}
----------------------------------------

As described above, the same set of factors that maintain the ES pluripotent state in culture also can induce this state in somatic cells. Although we had originally identified the six transcription factors as those that could maintain a hemangioblast state, we supposed that these factors might also induce the state. To test this notion, we transfected mouse embryonic fibroblasts (MEFs) or embryonic day 14.5 FL cells with the six factors and cultured them in the presence of doxycycline. The MEFs were employed as a test of transdifferentiation and the FL cells as a test of either transdifferentiation or dedifferentiation because the FL, at this stage, is a hematopoietic organ. Approximately 1 week after transfection, colonies with eHB morphology emerged from either source, at an observed frequency of almost 1:1000 transfected cells ([Figures 3](#fig3){ref-type="fig"}A and 3B). Three independent eHB lines expressing the six factors ectopically ([Figure S2](#app3){ref-type="sec"}A) derived from MEF or FL cells were established from single colonies and assayed for their ability to give rise to endothelial ([Figures 3](#fig3){ref-type="fig"}C, 3D, [S2](#app3){ref-type="sec"}B, and S2C), blood ([Figures 3](#fig3){ref-type="fig"}E, 3F, [S2](#app3){ref-type="sec"}D, and S2E), and smooth muscle ([Figures 3](#fig3){ref-type="fig"}G and [S2](#app3){ref-type="sec"}F) cells in the absence of doxycycline. The FL-eHBs were able to produce all three cell types. However, the MEF-eHBs tended to perform more poorly, particularly in the production of blood or smooth muscle cells, indicating that the factors do not fully reprogram MEFs, at least in the lines examined.

The eHBs derived from cultured cells (ESCs or MEFs) were often found with missegregations of the Y chromosome, possessing XYY, XO, or both ([Table S1](#app3){ref-type="sec"}). This result parallels the previously known instability of the Y chromosome in cultured murine ESCs ([@bib12]), except that here we detect cells not only containing XO, but also the counterpart XYY. However, all eHBs derived from uncultured FL cells tested so far possess a normal karyotype. These data indicate that primary cells (or perhaps female cells) may be the best sources from which to derive the eHBs.

RNA-Seq Analysis of eHBs and Their Derivatives {#sec2.4}
----------------------------------------------

The eHBs were next analyzed globally by RNA-seq to further assess their developmental status. We examined the transcriptomes of lines derived from ESC, FL, or MEF sources as well as their differentiated progeny and compared them with those of ESCs, ESC-derived KDR^+^ mesoderm cells (a population of cells that includes early hemangioblasts), and primary cell populations enriched for either embryonic endothelial cells (embryonic day 11.5 PECAM1^+^/CDH5^+^ cells dissociated from either the yolk sac or embryo), or FL HSCs (embryonic day 14.5 CD150^+^/CD201^+^/CD48^−^/CD45^+^ cells). We chose this latter cell type for comparison because it is a well-defined population of early hematopoietic progenitors ([@bib23]). The KDR^+^ mesoderm cells were obtained by differentiating ESCs 4 days as described in [Figure 1](#fig1){ref-type="fig"}A. The eHB-derived cells analyzed included the hematopoietic populations CDH5^+^/CD45^−^ and CDH5^+^/CD45^+^ (differentiated 2 or 3 days, respectively, as described in [Figure 2](#fig2){ref-type="fig"}D) and endothelial cells (differentiated 3 days as described in [Figure 2](#fig2){ref-type="fig"}A). When the transcriptomes of these populations were compared by principal component analysis ([Figure 4](#fig4){ref-type="fig"}A) or unsupervised hierarchical clustering ([Figure 4](#fig4){ref-type="fig"}B), a clear tendency was revealed. The eHBs grouped near ESC-derived KDR^+^ mesoderm cells and away from ESCs. The endothelial progeny of the eHBs grouped with the primary endothelial cells; the blood progeny of the eHBs grouped with FL HSCs. These data suggested the eHBs are trapped at or downstream of mesoderm development.

The examination of key marker genes further pinpointed the developmental state of the eHBs. In agreement with the clustering, canonical ESC genes like *Pou5f1* (*Oct4*) and *Sox2* are not expressed in the eHBs, and *Nanog* is poorly detected ([Figure 4](#fig4){ref-type="fig"}C). The eHBs express a number of genes associated with mesoderm ([Figure S3](#app3){ref-type="sec"}A), but do not express the transiently expressed mesoderm regulator *T* (*Brachyury*) or *Etv2* (*Er71*) ([Figure 4](#fig4){ref-type="fig"}D), a mesoderm factor expressed concomitantly with *T* that is required for the formation of the endothelial and hematopoietic lineages, in part by upregulating *Kdr* (*Flk1*) ([@bib26]). *Kdr* is inefficiently expressed in eHBs ([Figure 4](#fig4){ref-type="fig"}D), and the several lines tested by fluorescence-activated cell sorting (FACS) do not robustly stain for this marker (data not shown). The downregulation of *Kdr* is likely due to the ectopic expression of *Sox17*, as has been previously observed ([@bib34]). This notion is supported by the observation that *Kdr* expression increases in the endothelial or hemogenic endothelial (CDH5^+^/CD45^−^) progeny of the eHBs, as the ectopic expression of *Sox17* diminishes ([Figures 4](#fig4){ref-type="fig"}D and [S3](#app3){ref-type="sec"}B). These data indicate that eHBs are developmentally trapped downstream of *T* and *Etv2* expression and thus do not resemble early, canonical blast colony-forming cells (BL-CFCs) ([@bib6; @bib15; @bib16; @bib19]).

The blood or endothelial derivatives of eHBs express a number of hematopoietic and endothelial markers ([Figures 4](#fig4){ref-type="fig"}E, 4F, [S3](#app3){ref-type="sec"}B, and S3C). However, while the emerging blood cells generated from the eHBs express *Erg*, they fail to express *Hoxa9* and *Rora* ([Figure S3](#app3){ref-type="sec"}C). Collectively, these three factors have been previously shown to expand human blood progenitors with high CFU potential ([@bib11]). The absence of *Hoxa9* and *Rora* provides a possible explanation for why the eHBs generate CFUs poorly ([Figures 3](#fig3){ref-type="fig"}F and [S1](#app3){ref-type="sec"}I). The blood derivatives of the eHBs poorly express the definitive hematopoietic progenitor markers *Kit*, *Ly6a* (*Sca1*), or *Procr* (*Epcr*) ([Figures 4](#fig4){ref-type="fig"}E and 4F), an additional indication that the eHBs preferentially give rise to primitive hematopoiesis. The endothelial progeny of the eHBs better express these three markers, suggesting they may possess hemogenic potential, although this has not been observed. The endothelial progeny of the eHBs do not efficiently express the endothelial marker *VWF* ([Figure 4](#fig4){ref-type="fig"}F); however, this marker has variable expression across the developing murine vasculature ([@bib9]). The CDH5^+^/CD45^−^ progeny of the eHBs upregulate a number of endothelial genes whose expression then tends to diminish as the cells acquire CD45 expression ([Figures 4](#fig4){ref-type="fig"}D and 4F), further supporting the transiently endothelial-like nature of these cells.

A Central Role for FGF {#sec2.5}
----------------------

Because eHBs are trapped in a progenitor state, they afford the unique opportunity to examine growth factor signaling on a hemangioblast state prior to its commitment to a particular fate. The ESC-derived eHBs were originally found and maintained with doxycycline in Vm (N2B27 medium supplemented with the growth factors BMP4, FGF2, VEGF, and the small molecules SB431542 and Br-cAMP). In these conditions, the cells associate loosely, migrate as single cells or small groups ("scatter"), and at higher densities form flatter colonies with occasional domed colonies ([Figure 5](#fig5){ref-type="fig"}A; [Movie S1](#mmc2){ref-type="supplementary-material"}). The morphology of the cells changes as they move: the cells elongate, contract, and often exhibit pronounced lamellipodia. In Vm with doxycycline, the cell populations double on average every 16 hr ([Figure 5](#fig5){ref-type="fig"}B). In N2B27 medium containing doxycycline without any additional growth factors, the doubling slowed to an average of every 37 hr, and the cells converted to growth in domed colonies, reminiscent of how they often emerge prior to passaging ("No GFs" [Figures 5](#fig5){ref-type="fig"}A and 5B; [Movie S2](#mmc3){ref-type="supplementary-material"}). These observations indicated that one or more of the exogenous factors present in Vm were responsible for stimulating the eHBs to change their growth and morphological characteristics. To determine which factor(s) might be responsible, eHBs were maintained with doxycycline in N2B27 medium supplemented with single additional growth factors. In contrast to the addition of BMP4, the addition of FGF2 alone was sufficient to cause the cells to expand more efficiently, to scatter, and to form flatter colonies ([Figures 5](#fig5){ref-type="fig"}A and 5B; [Movie S3](#mmc4){ref-type="supplementary-material"}). The ability of FGF2 to exert these effects was not appreciably altered by the additional presence of BMP4 ([Figures 5](#fig5){ref-type="fig"}A and 5B).

To determine the means by which FGF2 was altering the growth and morphological characteristics of the eHBs, small molecule inhibitors were employed. For these assays, each inhibitor was titrated on the cells growing in N2B27 medium containing doxycycline and FGF2. In a dose-dependent manner, PD173074, a high-affinity inhibitor of the FGF receptor, phenocopied the absence of FGF2 ([Figures 5](#fig5){ref-type="fig"}C and 5D), indicating that FGF2 signals through its canonical receptors. The FGF receptors target multiple signaling pathways, including the MAPK/ERK or PI3K pathways (reviewed in [@bib14]). Indeed, the MEK (ERK kinase) inhibitors PD0325901 and U0126, or the PI3K inhibitor PI828, all revealed a dose-dependent inhibition on the expansion of the eHBs ([Figure 5](#fig5){ref-type="fig"}C). However, each of these three inhibitors alone could not fully mimic the morphological changes that occur in the absence of FGF2 ([Figure 5](#fig5){ref-type="fig"}D). Instead, the dual inhibition of the MEK and PI3K pathways better imitated the loss of FGF2 (less so with U0126, markedly with the higher affinity MEK inhibitor PD0325901) in the eHB line RB3.6.5. Furthermore, the PI3K activator 740 Y-P alone failed to promote the expansion of the eHBs in the absence of FGF2 ([Figure 5](#fig5){ref-type="fig"}E), supporting the notion that FGF2 exerts its effects on the eHBs through both MEK and PI3K signaling. It is not yet clear whether FGF2 activates additional signaling pathways in the eHBs, for example, the protein kinase C pathway ([@bib14]).

We wondered if, besides altering the proliferation and morphology of the eHBs, FGF2 might also be altering their fate decisions. Therefore, four independent eHB cell lines were tested for their ability to produce endothelial cells ([Figures 5](#fig5){ref-type="fig"}F and 5G), leukocytes (scored broadly as CD45^+^ cells; [Figure 5](#fig5){ref-type="fig"}H), and erythrocytes ([Figures 5](#fig5){ref-type="fig"}I and 5J) after being maintained in the absence or presence of FGF2. Cells maintained only in N2B27 medium with doxycycline tended to produce endothelial cells or leukocytes poorly. In contrast, cells additionally supplemented with FGF2 were better able to generate these cell types. This trend did not hold for the production of erythrocytes ([Figures 5](#fig5){ref-type="fig"}I and 5J). FGF2 did not consistently improve the efficiency by which the eHBs produced these cells; in fact, in some lines, the absence of FGF correlated with improved erythropoiesis (and improved viability of the differentiated cells, data not shown), a finding consistent with previous observations ([@bib63]). Taken together, these data indicate that FGF2 signaling is a key influence on the eHBs, promoting their expansion, altering their morphology, and poising them for vasculogenesis and leukopoiesis but not erythropoiesis.

Discussion {#sec3}
==========

We have uncovered a set of six transcription factors, *Gata2*, *Lmo2*, *Mycn*, *Pitx2*, *Sox17*, and *Tal1*, that collectively maintain cells in culture with the ability to give rise to blood, endothelial, or smooth muscle progeny. In the continued presence of the transcription factor(s), the progenitor populations expand over many generations and commit to a differentiation program as the ectopic factor(s) are downregulated by the withdrawal of doxycycline. We hypothesize the ability of the eHBs to remain in a proliferative progenitor state is a result of the enduring expression of *Mycn* and *Sox17* because these two factors are central for colony formation. The loss of *Sox17* disrupts hematopoiesis in the yolk sac and, more profoundly, within the embryo ([@bib24]). Recently, the transient, enforced expression of *Sox17* has been found to expand a hemogenic endothelial population that gives rise to multilineage hematopoietic cells ([@bib8; @bib34]). This activity is thought to occur through the Notch signaling pathway. Notch signaling also regulates *Myc* in murine hematopoietic progenitors ([@bib46]), but to our knowledge, it is unknown whether it likewise regulates *Mycn*. However, given the parallel functions of *Myc* and *Mycn* ([@bib30]), these data suggest the hemangioblast state might in part be maintained by persistent Notch signaling. Both *Mycn* and *Sox17* are employed repeatedly during development, and it is thus no surprise that they apparently are not enough, on their own, to maintain a hemangioblast state. This task, we hypothesize, is aided by the other four factors. Indeed, *Gata2*, *Lmo2*, or *Tal1* null embryos all die early in development with extreme hematopoietic deficiencies ([@bib50; @bib58; @bib62]). Ectopic *Lmo2*, in concert with *Mycn*, *Hlf*, *Meis1*, *Pbx1*, *Prdm5*, *Runx1t1*, and *Zfp37*, has recently been shown to reprogram blood cells to definitive HSCs ([@bib43]). Ectopic *Gata2*, *Tal1*, and *Etv2* promote the development of murine hemangioblasts, although it is not clear whether this combination of factors can sustain the expansion of the cells, or induce them from sources other than ESCs ([@bib28]).The expression of *Pitx2* is specific to HSCs when compared with differentiated blood cells ([@bib10]), and *Pitx2* null embryos die early with a number of developmental defects ([@bib27; @bib29]). However, *Pitx2* null HSCs do arise and give rise to differentiated blood progeny ([@bib69]), likely indicating some functional redundancy for this factor's participation in hematopoiesis in vivo.

We exploited the fact that the eHBs were trapped as progenitors to analyze the effect of specific growth factors upon them and uncovered a central role for FGF ([Figure 6](#fig6){ref-type="fig"}). These data are consistent with studies in which FGF promoted the expansion of BL-CFCs derived from human or murine ESCs ([@bib15; @bib60]) and high proliferative potential hemangioblasts from the murine AGM ([@bib67]). The eHBs provide a tractable means to study in fine detail the function of FGF or any other growth factors on the development of the blood and blood vessel lineages.

Our study parallels the work of other groups who have demonstrated the capacity of ectopic factors to expand progenitors in vitro; for example, *HOXB4* or *Myc* have been used to briefly propagate murine hematopoietic progenitors ([@bib46; @bib47]). More recent examples include employing *BCL-XL*, *BMI1*, and *MYC* to expand human megakaryocyte progenitors ([@bib35]); *Myc*, *Sox2*, and an shRNA targeting p53 to expand human erythroid progenitors ([@bib18]); and *ERG*, *HOXA9*, *MYB*, *RORA*, and *SOX4* to expand human hematopoietic progenitors with multilineage potential that can transiently give rise to erythroid or myeloid cells in vivo ([@bib11]). The ability to efficiently expand progenitors has broad implications; by identifying the "resident" proto-oncogenes in a given progenitor cell and then controlling them ectopically, it may be possible to trap, expand, and study many other types of progenitor cells and their differentiated progeny, particularly those that are not currently able to be maintained in culture.

Experimental Procedures {#sec4}
=======================

Mice Strains {#sec4.1}
------------

The following strains of mice were employed: B6.SJL-*Ptprc*^*a*^ *Pepc*^*b*^/BoyJ (Jackson, stock number 002014) and B6.Cg-*Gt(ROSA)26Sor*^*tm1(rtTA∗M2)Jae*^/J (Jackson, stock number 006965). Animal experiments and procedures were approved by the University of Wisconsin-Madison School of Medicine and Public Health Animal Care and Use Committee and were conducted in accordance with the Animal Welfare Act and Health Research Extension Act.

DNA Vectors {#sec4.2}
-----------

The cDNAs for rat *Gata2* and murine *Lmo2*, *Tal1*, *Sox17*, *Mycn*, *Pitx2*, *Hoxb5*, and *Rbp1* were obtained from Open Biosystems or GeneCopoeia encoded on Gateway Entry vectors or subsequently cloned into them. The sequence encoding *miR-130a* was amplified by PCR from murine genomic DNA and cloned into a Gateway Entry vector. All cDNAs on Entry vectors were then cloned, using Gateway LR clonase (Life Technologies), into a doxycycline-inducible expression cassette akin to a previously reported construction ([@bib1]) flanked by PiggyBac terminal repeats on a Gateway Destination vector. All vectors and their sequences are available upon request.

Isolation, Culture, and Cryopreservation of eHBs {#sec4.3}
------------------------------------------------

Colonies were picked under a dissecting microscope 5 to 8 days (depending on the starting cell type) after induction with 2 μg/ml doxycycline and dissociated by incubation in HEH (0.5 mM EDTA \[Fisher\] in 1 × Hank's balanced salt solution supplemented with 10 mM HEPES \[both from Life Technologies\]) for 5 to 10 min followed by trituration. Cells were pelleted and plated on Matrigel-coated plasticware in medium containing doxycycline. For each passage, typically every 2 days, cells were dissociated with HEH and replated, unless otherwise noted. Karyotype analyses were conducted at the WiCell Research Institute. To efficiently cryopreserve the eHBs, cells were resuspended in N2B27 medium and aliquoted to cyrotubes containing an equal volume of N2B27 medium with 10% DMSO (Sigma), for a final concentration of 5% DMSO, and gently inverted repeatedly to mix. The tubes were frozen in Nalgene "Mr. Frosty" freezing containers at −80°C and then placed in liquid nitrogen. Upon thawing rapidly in a 37°C water bath, cells were removed from tubes using large orifice tips, diluted into N2B27 medium, and pelleted to remove DMSO. All cell lines were cultured at 37°C and 5% CO~2~ in humidified incubators.
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![Screening for Hemangioblasts\
(A) Overview of the screening procedure.\
(B) Schematic representation of the inducible expression vectors employed.\
(C) An example of domed colonies arising 4 days after induction with doxycycline (top image). An example of passaged (expanded) colonies 14 days after induction with doxycycline (bottom image). Both images are phase contrast. White bars represent 100 μm.\
(D) Average colony number ± SD from at least three independent experiments in one ES line.\
(E) Average colony number ± SD in three independent ES lines.\
(F and G) Five domed colonies were pooled from each well and expanded in Vm containing doxycycline. The resulting isolates were evaluated by FACS. Example FACS dot plots are presented to the left; the box indicates cells considered positive for the marker(s) in isolates maintained with doxycycline (top graph) or the same isolates devoid of doxycycline for the indicated times (bottom graph). For each combination of factors, the results are independent experiments from two ES lines with at least one isolate per line. (F) Endothelial markers. (G) Hematopoietic marker employing the same isolates from (F) (^∗^p \< 0.05, ^∗∗^p \< 0.01, Wilcoxon rank sum test, one sided, comparing results with those from all nine factors).](gr1){#fig1}

![Characterization of the eHBs\
(A and B) Endothelial differentiation (3 days). (A) Endothelial markers. (B) Cells were incubated with fluorescently labeled Ac-LDL for 2 hr; 293T cells were employed as a negative control. The bar identifies cells efficiently taking up Ac-LDL.\
(C) Formation of capillary-like networks in Matrigel. Cells were differentiated for 7 days in Vm and then embedded in Matrigel for 10 days. White bars represent 400 μm.\
(D) Hematopoietic differentiation time course. The values represent the average percent of cells in each quadrant ± SD measured by FACS in three independent experiments of the eHB line RB3.6.5.\
(E) Erythrocyte differentiation (4 days).\
(F) Macrophage differentiation (9 days).\
(G) Megakaryocytes/proplatelet differentiation (4 days).\
(H) Smooth muscle differentiation (3 days).\
All example dot plots, images, and histograms are from the eHB line RB3.6.5. Two independent eHB cell lines (each established from a single colony) were maintained with doxycycline in Vm or differentiated in the absence of doxycycline ("−Dox"). (A and E--G) Example FACS dot plots are provided for each assay. The box indicates cells considered positive for the markers; these values are summarized in the adjacent bar graphs as the average percent of positive cells ± SD from three independent experiments of each line. (B and H) Example histograms are provided for each assay. The bar represents cells considered positive. These values are compiled in the adjacent bar graphs as the average percent of cells ± SD from at least three independent experiments of each line. See also [Figure S1](#app3){ref-type="sec"} and [Table S1](#app3){ref-type="sec"}.](gr2){#fig2}

![The eHBs Can Be Derived from Different Cell Sources\
(A and B) Colonies present 8 days (E14.5 FL cells) or 7 days (MEFs) after transfection. (A) Example phase contrast images of colonies. The eHBs can arise as domed colonies (left and middle images) and/or scattered colonies (right image). White bars represent 100 μm. (B) Quantification of domed and/or scattered eHB colonies. Results are the average ± SD of three independent experiments.\
(C--E and G) FACS analysis of endothelial (C and D), blood (E), and smooth muscle (G) cells arising from the eHBs, differentiated as described in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. The results from three independent lines, each established from a single colony derived from FL or MEF cells, are shown for every assay (each line tested once), except for (G), which shows results from only two MEF-eHB lines because the third repeatedly failed to produce sufficient live differentiated cells for analysis.\
(F) Hematopoietic CFUs from the indicated eHB lines. Results are from one (FL lines) or two (MEF lines, average ± SD shown) independent experiments.\
The eHB lines were induced and maintained with doxycycline in N2B27 medium supplemented with FGF2. See also [Figure S2](#app3){ref-type="sec"} for additional data including example FACS dot plots, histograms, and images of hematopoietic colonies and [Table S1](#app3){ref-type="sec"}.](gr3){#fig3}

![RNA-Seq Uncovers the Developmental State of the eHBs\
(A) Principal component analysis.\
(B) Unsupervised hierarchical clustering.\
(C--F) Expression levels of select marker genes measured by RNA-seq. The y axes are in log~10~ scaling with a threshold of detection cutoff of 1 transcript per million (TPM). Box sizes represent the minimum to maximum TPM values of the samples described in (A) and (B); the line inside the boxes represents the mean. (C) ESC markers. (D) Mesoderm markers. (E) Hematopoietic markers. (F) Endothelial markers.\
RNA-seq analysis was performed on ESCs and their derivatives, on eHBs and their derivatives, on primary E14.5 FL HSCs, and on primary E11.5 endothelial cells (ECs). Five eHB lines were employed, two derived from ESCs, two derived from FL cells, and one derived from MEFs. See also [Figure S3](#app3){ref-type="sec"} and [Table S1](#app3){ref-type="sec"}.](gr4){#fig4}

![The Effect of FGF on the eHBs\
(A) Phase contrast example images of the eHB line RB3.6.5 in different maintenance media. White bars represent 100 μm.\
(B) Growth curve of eHB lines in different maintenance media.\
(C) Titration of small molecule inhibitors in N2B27 medium containing doxycycline and FGF2.\
(D) Phase contrast example images of the eHB line RB3.6.5 grown in medium as (C) for 2 days in the presence of the indicated small molecule inhibitors. White bars represent 100 μm.\
(E) Growth in N2B27 medium containing doxycycline, with or without the PI3K activator 740 Y-P (Tocris).\
(F--I) FACS analysis of the differentiated progeny from four independent eHB lines (each line tested at least once, for replicates the average is shown) maintained in N2B27 medium containing doxycycline, with or without FGF2. Differentiated and scored as exemplified in [Figures 1](#fig1){ref-type="fig"} or [2](#fig2){ref-type="fig"}. (F and G) Endothelial differentiation. (F) Endothelial markers. (G) Ac-LDL uptake. (H) The pan-leukocyte marker CD45. (I) The erythrocyte marker TER119.\
(J) Measurements by quantitative PCR of the expression level of embryonic (*Hbb-bh1*) and adult hemoglobin (*Hbb-b1*) in cultures described in (I). The y axis is on a log~10~ scale.\
Results are from eHB cell lines maintained with doxycycline in N2B27 medium ("No GFs") or in N2B27 medium supplemented with FGF2, BMP4, both FGF2 and BMP4, or Vm. (B, C, and E) Box sizes represent the minimum to maximum number of cumulative population doublings measured at the indicated times in four to five independent eHB lines (each tested at least once); the line inside the boxes represents the mean. Two ESC-derived eHBs and two or three FL-derived eHBs were employed. See also [Table S1](#app3){ref-type="sec"} and [Movies S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}.](gr5){#fig5}

![Proposed Model for the Role of FGF in the eHBs\
The binding of FGF to its receptor(s) ([@bib42]) appears to foster signaling in the eHBs through at least the MEK and PI3K signaling pathways. Perhaps collectively, these pathways (1) alter the morphology and migration of the eHBs, (2) cause the eHBs to expand efficiently, and (3) prime the eHBs to generate endothelial cells and leukocytes. The small molecule inhibitors employed in this study and their targets are depicted.](gr6){#fig6}
